Huang et al.[15] found that treatment with bevacizumab (anti-VEGF monoclonal antibody), administered 14 days after ovariectomized mice were xenografted with human adenomyosis lesions at week eight, decreased the MVD and the expression of VEGF. Here, VEGFA is linked to adenomyosis.